Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

This study has been completed.
Novartis Pharmaceuticals
Walther Cancer Institute
Information provided by (Responsible Party):
Daniela Matei, MD, Hoosier Cancer Research Network Identifier:
First received: September 12, 2005
Last updated: February 17, 2016
Last verified: February 2016